Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00852969 · ClinicalTrials.gov registry record · Phase 4
Niacin and Endothelial Function in Early CKD
A Phase 4 study, sponsored by Tufts Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00852969 is a Phase 4 study that has completed, run by Tufts Medical Center. The registered enrollment target is 30 participants.
The verdict
NCT00852969, a Phase 4 study, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to obtain information on whether raising levels of HDL-cholesterol (the "good" cholesterol) can improve how blood vessels work in kidney disease. This may help us understand the causes leading to high rates of heart disease in kidney disease and also ways to reduce this risk.
Interventions
- DRUG Niacin
- DRUG Active Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00852969
The ClinicalTrials.gov registry entry for NCT00852969 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Niacin is the first listed.
NCT00852969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00852969 about?
NCT00852969 is a clinical study titled "Niacin and Endothelial Function in Early CKD". The purpose of this study is to obtain information on whether raising levels of HDL-cholesterol (the "good" cholesterol) can improve how blood vessels work in kidney disease. This may help us understand the causes leading to high rates of heart disease in kidney disease and also ways to reduce this ...
What is the current status of trial NCT00852969?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2008-08. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00852969?
The interventions under investigation include: Niacin (DRUG), Active Placebo (DRUG).
Who is sponsoring clinical trial NCT00852969?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.